LAFAYETTE, La., June 09, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader of in-home, technology-enabled post-acute respiratory care, today announced that its Board of Directors has authorized a share repurchase program, effective through June 2026. Under the share repurchase program, Viemed may purchase up to 1,976,441 common shares of the Company (“the Common Shares”) from time to time in accordance with applicable securities laws, representing a ...

LAFAYETTE, La., June 03, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced it will present at the East Coast IDEAS Investor Conference on Wednesday June 11, 2025 at The Westin Times Square in New York, NY. Viemed’s presentation is scheduled to begin at 11:30am ET. The presentation is webcast and can be accessed through the conference host’s main website: http ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number: 001-38973 Viemed Healthcare, Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada N/A (State or other ...

VIEMED HEALTHCARE ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS LAFAYETTE, Louisiana (May 7, 2025) Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2025, and updated guidance for the full year ending December 31, 2025. Operational highlights (all dollar amounts are USD): Agreement to Acquire Lehan's Med ...

LAFAYETTE, La., May 07, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2025, and updated guidance for the full year ending December 31, 2025. Operational highlights (all dollar amounts are USD): Net revenues for the quarter ended March 31, 2025 were $59.1 million, representing ...

LAFAYETTE, La., April 22, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced that it will host its First Quarter 2025 Earnings Conference Call on Thursday, May 8, 2025, at 11:00 a.m. EDT. Interested parties may participate in the call by dialing: (866) 682-6100 (US Toll-Free) +1 (862) 298-0702 (International) Live Audio Webcast: https://event.choruscall.com/me ...

Core Viewpoint - Viemed Healthcare, Inc. (NASDAQ: VMD) is a US-based provider of home medical respiratory equipment, which has been identified as an undervalued stock with strong fundamentals and potential for income generation through investment strategies [1]. Company Summary - The stock was trading at approximately $7.35 per share over seven months ago when the bullish stance was initiated [1]. - The company focuses on acquiring undervalued profitable stocks with strong balance sheets and minimal debt, indicating a solid financial position [1]. Investment Strategy - The investment approach includes writing calls against positions to generate additional income when opportunities arise [1]. - Risk management is emphasized through position sizing and the use of trailing stop losses over time, showcasing a disciplined investment strategy [1].

Financial Data and Key Metrics Changes - The company reported a 20% year-over-year increase in revenue for Q4 and a 23% increase for the full year 2024, achieving record revenue levels [28] - Adjusted EBITDA grew 11% for the quarter to $14.2 million and 19% for the full year, with adjusted EBITDA margins at 23.5% for Q4 and 22.8% for the full year [34][43] - Free cash flow was $11.6 million in 2024, representing 5.2% of revenue, compared to $21.7 million or 11.9% of revenue in 2023 [40] Business Line Data and Key Metrics Changes - The vent business accounted for 55% of revenue in Q4 and 56% for the year, with a 4.4% sequential increase in vent revenue [30][19] - The sleep business saw a nearly 10% sequential increase in sleep therapy patients, leading to a 43% increase in 2024 compared to 2023 [22] - Staffing and oxygen businesses each contributed roughly 10% to both Q4 and full year revenue [31] Market Data and Key Metrics Changes - The company identified a significant underserved patient population in complex respiratory care, with 25 million patients suffering from COPD in the US [9] - The market penetration for respiratory care is currently in the high single digits, indicating substantial growth potential [10] Company Strategy and Development Direction - The company aims to focus on organic growth while exploring potential inorganic growth opportunities, particularly in behavioral health [25] - The strategic goal for 2025 includes aggressively increasing the sales force and capitalizing on unique positioning in behavioral health [25][43] - The company is positioned to help hospitals manage length of stay and improve patient outcomes, especially under financial strain [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth outlook for 2025, projecting net revenue between $254 million and $265 million, implying a 16% growth at the midpoint [43] - The company is optimistic about the potential for M&A activity, noting increased interest and a more favorable environment compared to previous years [60] Other Important Information - The company has a strong balance sheet with no net debt and significant cash available for future investments [41][42] - The introduction of a behavioral health offering is seen as a key growth area, with staffing needs driven largely by behavioral health services [12][73] Q&A Session Summary Question: Anticipated impact from new administration tariffs - Management has not seen any impact from potential tariffs yet, as most products are sourced domestically [51] Question: Competitive bidding environment - No whispers of competitive bidding have been heard, and it is unlikely to be a concern until at least 2027 [56][57] Question: M&A environment - The company sees a more target-rich environment for M&A compared to previous years, with increased interest and options available [60] Question: Joint venture performance - The joint venture with East Alabama Medical has been profitable and successful, but future ventures will need to be of substantial size to justify the effort [66][68] Question: Cash flow acceleration - Management expects cash flow to increase as the business grows, despite recent CapEx needs due to vent growth [78][80]

Financial Performance - For the year ended December 31, 2024, the company generated revenues of $224.3 million, a 22.5% increase from $183.0 million in 2023, with net income rising to $11.4 million from $10.2 million[177]. - For the year ended December 31, 2024, total revenue was $224.3 million, an increase of $41.2 million (22.5%) compared to 2023[194]. - Net income for 2024 was $11.4 million, an increase of $1.2 million (11.4%) from the previous year, with a net income margin decrease to 5.1%[204]. - The company reported a net income of $11.4 million for 2024, up 11.5% from $10.2 million in 2023[241]. - The company’s operating income for 2024 was $17.9 million, up from $14.3 million in 2023, representing a 25.5% increase[241]. - Adjusted EBITDA for the year ended December 31, 2024, was $14.2 million, reflecting the company's operating performance[206]. - Basic earnings per share for 2024 was $0.29, compared to $0.27 in 2023 and $0.16 in 2022[358]. Revenue Breakdown - Revenue from the rental and sale of home medical equipment accounted for 91.0% of total revenue in 2024, compared to 94.2% in 2023[177]. - Ventilator rental revenue increased by $16.3 million (15.1%) due to higher patient volumes, while rental revenue from other home medical equipment rose by $10.3 million (27.0%)[194]. - Rental revenue from ventilator rentals increased to $124.6 million in 2024, compared to $108.3 million in 2023, representing a growth of 15.1%[277]. - Revenue from other home medical equipment rentals rose to $48.7 million in 2024, a 27.0% increase from $38.3 million in 2023[277]. - The company recorded $30.9 million in equipment and supply sales for 2024, up 19.3% from $25.8 million in 2023[277]. - Medicare revenues accounted for 41% of the company's traditional revenue streams in 2024, down from 44% in 2023 and 47% in 2022[277]. Expenses and Profitability - Selling, general and administrative expenses totaled $106.2 million, an increase of $18.3 million (20.8%), but as a percentage of revenue improved to 47.4%[197]. - Research and development costs increased to $3.1 million, reflecting a rise of $0.3 million (10.3%) from 2023[198]. - The company's gross profit for 2024 was $133.2 million, representing a gross margin of 59.4% compared to 61.7% in 2023[241]. - Gross profit margin for the quarter ended December 31, 2024, was 60%, consistent with the previous quarter[188]. - The provision for income taxes was $4.8 million, compared to $4.1 million in 2023, with an estimated effective tax rate of 29.4%[203]. Cash Flow and Liquidity - Cash and cash equivalents increased to $17.5 million as of December 31, 2024, up from $12.8 million in 2023, indicating improved liquidity[208]. - Net cash provided by operating activities for the year ended December 31, 2024 was $39.1 million, a decrease from $45.2 million in 2023[210][212]. - Net cash used in investing activities was $30.7 million in 2024, which included $27.5 million for capital expenditures, representing a 17% increase year-over-year[213]. - Net cash used in financing activities was $3.7 million in 2024, with principal payments on the 2022 Revolving Credit Facility totaling $5.0 million[215]. Assets and Liabilities - Total current assets rose to $52.9 million at December 31, 2024, from $38.4 million at December 31, 2023, marking a 37.9% increase[239]. - Total assets grew to $177.1 million at December 31, 2024, compared to $154.9 million at December 31, 2023, a 14.3% increase[239]. - Shareholders' equity increased to $133.3 million at December 31, 2024, from $113.9 million at December 31, 2023, reflecting a 17.0% growth[239]. - The Company’s long-term debt decreased from $6.002 million in 2023 to $3.589 million in 2024, while the current portion of debt also reduced significantly[307]. - Total accrued liabilities rose to $20.157 million in 2024 from $17.578 million in 2023, with accrued bonuses payable decreasing to $6.589 million[306]. Market Outlook and Growth - The company anticipates a Compound Annual Growth Rate (CAGR) of approximately 6% for respiratory devices and 8% for Obstructive Sleep Apnea (OSA) devices, indicating a robust growth trajectory in the home medical equipment market[179]. - U.S. home healthcare spending is projected to reach $250 billion by 2031, with a CAGR of approximately 7%[181]. - The company expects continued growth in its active ventilator patient base and other home medical offerings as it expands geographically[195]. - The company is positioned to benefit from the transition to value-based healthcare, which emphasizes home care over acute care settings[181]. Acquisitions and Investments - The company acquired East Alabama HomeMed, LLC for $3.0 million during 2024, contributing to the total cash used in investing activities[213]. - The Company acquired a controlling 60% equity interest in East Alabama HomeMed, LLC for a total goodwill of $3.2 million and a trade name valued at $0.4 million[300]. - The acquisition of Home Medical Products, Inc. was completed for approximately $29 million in cash, resulting in a goodwill of $29.765 million due to synergies and cost savings[301][302]. Stock and Compensation - Stock-based compensation expenses rose to $6.3 million, an increase of $0.4 million (7.5%) from 2023[199]. - The Company had outstanding options of 3,917,000 and restricted stock units (RSUs) of 1,514,000 as of December 31, 2024[335]. - The Company issued 915,043 RSUs during the year ended December 31, 2024, with a fair value between $7.05 and $8.39 per share[341]. - The total liability associated with PSUs at December 31, 2024, is $2,546,000, with $1,700,000 included in current accrued liabilities and $846,000 in long-term accrued liabilities[343].

Financial Performance - Net revenues for Q4 2024 reached a record $60.7 million, an increase of $10.0 million, or 20%, compared to Q4 2023[4] - Total net revenues for the year 2024 were $224.3 million, an increase of $41.2 million, or 23%, over 2023[4] - Net income for Q4 2024 was $4.3 million, or $0.10 per diluted share, a 24% increase from Q4 2023[4] - Net income attributable to Viemed Healthcare, Inc. for the year ended December 31, 2024, was $11,265 thousand, representing a 9.9% increase from $10,243 thousand in 2023[13] - Basic net income per share for the year ended December 31, 2024, was $0.29, up from $0.27 in 2023[13] EBITDA and Cash Flow - Adjusted EBITDA for the year 2024 was a record $51.1 million[4] - Adjusted EBITDA for the year ended December 31, 2024, was $51,107 thousand, compared to $43,064 thousand in 2023, reflecting an 18.7% increase[18] - Free Cash Flow for 2024 totaled $11.6 million, down from $21.7 million in 2023[4] - Cash flows from operating activities for the year ended December 31, 2024, were $39,089 thousand, down from $45,212 thousand in 2023[15] - Net cash provided by operating activities decreased to $39,089,000 in 2024 from $45,212,000 in 2023, a decline of 13.5%[22] - Free Cash Flow for 2024 was $11,639,000, down from $21,707,000 in 2023, representing a decrease of 46.3%[22] Revenue Breakdown - Revenue for the year ended December 31, 2024, increased to $224,257 thousand, a 22.6% increase from $183,008 thousand in 2023[13] - Revenue from ventilator rentals (non-invasive and invasive) rose by 15.1% to $124,577,000, accounting for 55.6% of total revenue in 2024[22] - Other home medical equipment rentals saw a significant increase of 27.0%, reaching $48,651,000 in 2024[22] - Equipment and supply sales grew by 19.9% to $30,896,000, representing 13.7% of total revenue in 2024[22] - Service revenues surged by 88.8%, totaling $20,133,000 in 2024, up from $10,665,000 in 2023[22] Patient Count and Market Expansion - The ventilator patient count increased to 11,795, a 14% increase year-over-year[4] - The PAP therapy patient count rose to 21,338, a 43% increase year-over-year[4] - The company plans to ramp up its sales force to penetrate the underserved market for non-invasive ventilation and complementary services[5] Future Projections - The company expects net revenue for 2025 to be in the range of $254 million to $265 million[4] - Adjusted EBITDA for 2025 is expected to be between $54 million and $58 million[4] Investment and Cash Management - Net cash used in investing activities for the year ended December 31, 2024, was $(30,699) thousand, compared to $(52,113) thousand in 2023, indicating improved cash management[15] - The company reported a net increase in cash and cash equivalents of $4,701 thousand for the year ended December 31, 2024, compared to a decrease of $(4,075) thousand in 2023[15] - The company invested $37,771 thousand in property and equipment during the year ended December 31, 2024, compared to $26,093 thousand in 2023, indicating ongoing expansion efforts[15] Shareholder Information - The weighted average number of diluted shares outstanding increased to 40,805,085 for the year ended December 31, 2024, from 40,378,922 in 2023[13]